The lipid nanoparticle (LNP) delivery system is a revolutionary discovery that has enabled gene therapies and efficient mRNA vaccines.[19] LNP has been considered for application in the treatment of non‐cancer liver diseases such as liver fibrosis.[20] To test our hypothesis of whether HERC2 overexpressed plasmids delivered by LNP are able to mitigate DILI, we constructed LNP‐wrapped HERC2 overexpressed plasmids (Figure7A; Figure S4, Supporting Information). The gene discussed is HERC2; the disease is Hepatic fibrosis.